Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia

Blood

Volumn 130, Issue 21, 2017, Pages 2317-2325

  Mueller, Karen Thudium ^a   Maude, Shannon L ^b,c   Porter, David L ^c   Frey, Noelle ^c   Wood, Patricia ^a   Han, Xia ^a   Waldron, Edward ^a   Chakraborty, Abhijit ^a   Awasthi, Rakesh ^a   Levine, Bruce L ^c   Melenhorst, J Joseph ^c   Grupp, Stephan A ^b,c   June, Carl H ^c   Lacey, Simon F ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; GENOMIC DNA; INTERLEUKIN 6; TISAGENLECLEUCEL T; TOCILIZUMAB; CTL019 CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADOPTIVE TRANSFER; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD; BONE MARROW; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL KINETICS; CEREBROSPINAL FLUID; CHILD; CHILDHOOD LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COHORT ANALYSIS; CYTOKINE RELEASE SYNDROME; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EVENT FREE SURVIVAL; FLOW CYTOMETRY; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; NEUROLOGICAL COMPLICATION; NORMAL VALUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; SURVIVAL ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSGENE; TREATMENT RESPONSE; TUMOR VOLUME; YOUNG ADULT; BONE MARROW CELL; CELL PROLIFERATION; DRUG EFFECTS; INFANT; KINETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; RECURRENT DISEASE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE MARROW CELLS; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; CYTOKINES; HUMANS; INFANT; KINETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; RECURRENCE; TRANSGENES; TUMOR BURDEN; YOUNG ADULT;

EID: 85034844703     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-06-786129     Document Type: Article

References (33)

1. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453-1464.
2. Bridgeman JS, Ladell K, Sheard VE, et al. CD3z-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy. Clin Exp Immunol. 2014;175(2):258-267.
3. Long A, Haso W, Smith J, et al. 4-1BB costimulation ameliorates exhaustion and prolongs in vivo persistence of chimeric antigen receptor (CAR) expressing T cells [abstract]. Cancer Res. 2015;75(suppl 15). Abstract 4702.
4. Lee DY, Choi BK, Lee DG, et al. 4-1BB signaling activates the t cell factor 1 effector/b-catenin pathway with delayed kinetics via ERK signaling and delayed PI3K/AKT activation to promote the proliferation of CD81 T Cells. PLoS One. 2013; 8(7):e69677.
5. Grupp SA, Maude SL, Shaw PA, et al. Durable remissions in children with relapsed/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019) [abstract]. Blood. 2015;126(23). Abstract 681.
6. Maude SL, Teachey DT, Rheingold SR, et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL [abstract]. J Clin Oncol. 2016;34(15). Abstract 3011.
7. Porter DL, Frey NV, Melenhorst JJ, et al. Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory CLL [abstract]. J Clin Oncol. 2016;34(15). Abstract 3009.
8. Grupp SA, Laetsch TW, Buechner J, et al. Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) [abstract]. Blood. 2016;128(22). Abstract 221.
9. Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45(2):e124-e131.
10. Turtle CJ, Hanafi LA, Berger C, et al. CD19 CART cells of defined CD41:CD81 composition in adult B cell ALL patients. J Clin Invest. 2016; 126(6):2123-2138.
11. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-528.
12. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16): 1507-1517.
13. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2): 188-195.
14. Lee DW, Stetler-Stevenson M, Yuan CM, et al. Safety and response of incorporating CD19 chimeric antigen receptor T cell therapy in typical salvage regimens for children and young adults with acute lymphoblastic leukemia [abstract]. Blood. 2015;128(23). Abstract 684.
15. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.
16. Porter D, Frey N, Melenhorst J, et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL [abstract]. Blood. 2014; 124(21). Abstract 1982.
17. Janetzki S, Britten CM, Kalos M, et al. “MIATA”-minimal information about T cell assays. Immunity. 2009;31(4):527-528.
18. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95): 95ra73.
19. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-733.
20. National Comprehensive Cancer Network Guidelines. Acute lymphoblastic leukemia. V2.2016. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed 2 October 2017.
21. National Comprehensive Cancer Network Guidelines. Chronic lymphocytic leukemia/small lymphocytic lymphoma. V2.2017. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf. Accessed 2 October 2017.
22. Porter DL, Kalos M, Zheng Z, Levine B, June C. Chimeric antigen receptor therapy for B-cell malignancies. J Cancer. 2011;2:331-332.
23. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16): 1509-1518.
24. Ho M, Armstrong J, McMahon D, et al. A phase 1 study of adoptive transfer of autologous CD81 T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS. Blood. 1993;81(8):2093-2101.
25. Walker RE, Bechtel CM, Natarajan V, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood. 2000; 96(2):467-474.
26. Read EJ, Keenan AM, Carter CS, Yolles PS, Davey RJ. In vivo traffic of indium-111-oxine labeled human lymphocytes collected by automated apheresis. J Nucl Med. 1990;31(6): 999-1006.
27. Rheingold SL, Chen LN, Maude SL, et al. Efficient trafficking of chimeric antigen receptor (CAR)modified T cells to CSF and induction of durable CNS remissions in children with CNS/combined relapsed/refractory ALL [abstract]. Blood. 2015; 126(23). Abstract 3769.
28. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
29. Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664-679.
30. Maude SL, Barrett DM, Rheingold SL, et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL [abstract]. J Clin Oncol. 2016;128(22):217. Abstract 3007.
31. Brusa D, Serra S, Coscia M, et al. The PD-1/ PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013;98(6):953-963.
32. 1 composition in adult B-cell ALL patients. J Clin Invest. 2016; 126(6):2123-2138.
33. Schuster SJ, Bishop MR, Tam C, et al. Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) - an interim analysis [abstract]. Hematol Oncol. 2017;35(suppl 2):27. Abstract LB2604.